Previous 10 | Next 10 |
2024-01-08 07:54:50 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript Abeona shares jump after FDA priority review for epidermolysis bullosa drug Abeona Therapeutics GAAP EPS of -$0.48 beats by $0.05 Seeking Alpha...
CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P. The credit agreement, which has a term of three and a half years, includes a first tranche o...
2023-11-27 07:50:10 ET More on Abeona Therapeutics Abeona Therapeutics Inc. (ABEO) Q3 2023 Earnings Call Transcript Abeona Therapeutics GAAP EPS of -$0.48 beats by $0.05 Abeona submits FDA market application for rare skin disorder drug Seeking Alpha’s ...
- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has ac...
2023-11-16 16:26:04 ET Abeona Therapeutics Inc. (ABEO) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Greg Gin - Vice President of Investor Relations & Corporate Communications Vishwas Seshadri - President, CEO and Director ...
2023-11-13 07:48:31 ET More on Abeona Therapeutics Abeona submits FDA market application for rare skin disorder drug Abeona plans marketing submission for lead asset after FDA meeting Seeking Alpha’s Quant Rating on Abeona Therapeutics Historical earni...
Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly known as EB-101) in recessive dystrophic epidermolysis bullosa (RDEB) expected by ...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Abeona Therapeutics Inc. (ABEO) is expected to report $-0.53 for Q3 2023
CLEVELAND, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On October 31, 2023, th...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced that members of its senior management team wi...
CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. Eastern Time. The Company will a...
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter ...